Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Rhythm Biosciences Ltd has acquired the Genetype genetic risk assessment business assets, enhancing its oncology portfolio and offering immediate revenue opportunities. This strategic move is expected to diversify Rhythm’s capabilities and accelerate growth by leveraging Genetype’s existing customer base and skilled workforce in Australia and the USA. The integration of Genetype’s proteomic and genomic technologies promises to expand Rhythm’s market reach and boost shareholder returns.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.